Public Markets Freeneome recently completed a SPAC merge and began trading as FRNM on Nasdaq, signaling enhanced visibility and access to public funding channels. This momentum can be leveraged to introduce scalable, payer-ready cancer screening solutions to insurers and hospital networks seeking innovative, clinically validated tests.

FDA Endorsements Recent FDA Breakthrough Device Designation for SimpleScreen Lung and FDA approval for SimpleScreen CRC create strong regulatory validation and credibility. Target health systems, payers, and ACOs with these endorsements to accelerate adoption of multi-disease early-detection tests within colorectal and lung cancer screening programs.

Strategic Partnerships Abbott collaboration to commercialize colorectal screening in the U.S. demonstrates a go-to-market model with large-scale distribution. Pursue co-development or distribution deals with major pharma, diagnostics, and lab networks to expand reach, leverage existing reimbursement pathways, and accelerate patient access.

Multiomics Platform Freeneome’s AI/ML-enabled multiomics approach positions it for enterprise lab integration and payer-driven value propositions. Sales pitches can emphasize workflow compatibility with existing lab informatics, cloud infrastructure, and scalable data analytics to reduce time-to-result and improve screening economics.

Expansion Opportunities Phase one products target colorectal cancer with upcoming lung cancer and broader multi-cancer screening potential. Identify opportunities with health systems investing in population health, cancer screening programs, and preventive care initiatives to capture incremental testing volumes and enhance preventive care metrics.